Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · Real-Time Price · USD
18.05
-0.20 (-1.10%)
Aug 3, 2026, 4:00 PM EDT - Market closed
Avalo Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 24.99 | 15.86 | 134.55 | 7.42 | 13.17 | 54.59 |
Short-Term Investments | 57.01 | 82.48 | - | - | - | - |
Cash & Short-Term Investments | 81.99 | 98.34 | 134.55 | 7.42 | 13.17 | 54.59 |
Cash Growth | -34.43% | -26.91% | 1714.51% | -43.71% | -75.87% | 188.52% |
Accounts Receivable | - | - | - | - | - | 1.06 |
Other Receivables | - | - | - | 0.14 | 1.92 | 3.74 |
Total Trade Receivables | - | - | - | 0.14 | 1.92 | 4.8 |
Inventory | - | - | - | - | 0.02 | 0.04 |
Other Current Assets | 6.83 | 6.95 | 4.34 | 0.84 | 1.31 | 2.42 |
Total Current Assets | 88.83 | 105.29 | 138.89 | 8.4 | 16.42 | 61.85 |
Net Property, Plant & Equipment | 0.38 | 0.46 | 1.21 | 1.97 | 2.41 | 2.7 |
Other Intangible Assets | - | - | - | - | - | 0.04 |
Goodwill | 10.5 | 10.5 | 10.5 | 10.5 | 14.41 | 14.41 |
Other Long-Term Assets | 0.18 | 0.21 | 0.13 | 0.13 | 0.13 | 1.23 |
Total Assets | 99.89 | 116.46 | 150.73 | 20.99 | 33.37 | 80.21 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 0.36 | 0.14 | 0.28 | 0.45 | 2.88 | 3.37 |
Accrued Expenses | 11.24 | 12.8 | 6.32 | 4.17 | 13.21 | 16.52 |
Short-Term Debt | - | - | - | - | 5.93 | - |
Unearned Revenue | - | - | - | - | 0.09 | - |
Other Current Liabilities | - | - | 0.36 | - | - | - |
Total Current Liabilities | 11.6 | 12.94 | 6.96 | 4.62 | 22.11 | 19.89 |
Long-Term Debt | - | - | - | - | 13.49 | 32.83 |
Other Long-Term Liabilities | 19.97 | 20.47 | 10.74 | 9.07 | 8.68 | 4.41 |
Total Long-Term Liabilities | 19.97 | 20.47 | 10.74 | 9.07 | 22.17 | 37.24 |
Total Liabilities | 31.57 | 33.41 | 17.7 | 13.69 | 44.28 | 57.13 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.03 | 0.02 | 0.01 | 0 | 0 | 0.01 |
Additional Paid-in Capital | 536.45 | 531.49 | 503.29 | 342.44 | 292.91 | 285.24 |
Accumulated Other Comprehensive Income | -0.01 | 0.07 | - | - | - | - |
Retained Earnings | -468.15 | -448.52 | -370.26 | -335.13 | -303.82 | -262.17 |
Shareholders' Equity | 68.32 | 83.05 | 133.03 | 7.3 | -10.92 | 23.08 |
Total Liabilities & Equity | 99.89 | 116.46 | 150.73 | 20.99 | 33.37 | 80.21 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | - | 0 | 0 | 0 | 19.42 | 32.83 |
Net Cash (Debt) | 81.99 | 98.34 | 134.55 | 7.42 | -6.24 | 21.75 |
Net Cash Growth | -34.43% | -26.91% | 1714.51% | - | - | 14.97% |
Net Cash Per Share | 5.19 | 7.34 | 17.95 | 26.70 | -159.28 | - |
Book Value | 68.32 | 83.05 | 133.03 | 7.3 | -10.92 | 23.08 |
Book Value Per Share | 4.33 | 6.20 | 17.75 | 26.30 | -278.43 | - |
Tangible Book Value | 57.82 | 72.55 | 122.53 | -3.2 | -25.32 | 8.64 |
Tangible Book Value Per Share | 3.66 | 5.41 | 16.35 | -11.51 | -645.99 | - |